Can the Dose of Belimumab be Reduced in Patients with Systemic Lupus Erythematosus?

Autor:	Rua-Figueroa I; Department of Rheumatology, Hospital Universitario Doctor Negrín, Las Palmas de Gran Canaria, Spain., Altabás-González I; Department of Rheumatology, Complexo Hospitalario Universitario de Vigo, Vigo, Spain.; Galicia Sur Health Research Institute, Rheumatology and Inmuno-Mediated Diseases Reasearch Group (IRIDIS), Vigo, Spain., Mouriño C; Department of Rheumatology, Complexo Hospitalario Universitario de Vigo, Vigo, Spain.; Galicia Sur Health Research Institute, Rheumatology and Inmuno-Mediated Diseases Reasearch Group (IRIDIS), Vigo, Spain., Roberts K; Argentina Society of Rheumatology, Research Unit, Buenos Aires, Argentina., Hernández-Martín A; Department of Rheumatology, Hospital Universitario Doctor Negrín, Las Palmas de Gran Canaria, Spain., Casafont-Solé I; Department of Rheumatology, Germans Trias i Pujol University Hospital, LCMN, Germans Trias i Pujol Research Institute (IGTP), Barcelona, Spain., Font-Urgelles J; Department of Rheumatology, Germans Trias i Pujol University Hospital, LCMN, Germans Trias i Pujol Research Institute (IGTP), Barcelona, Spain., Román-Ivorra JA; Department of Rheumatology, Hospital Universitari i Politècnic La Fe, Valencia, Spain.; Facultad de Medicina y Ciencias de la Salud. Universidad Católica de Valencia, Valencia, Spain., Navarro MR; Department of Rheumatology, Hospital Universitari i Politècnic La Fe, Valencia, Spain., Galindo-Izquierdo M; Department of Rheumatology, University Hospital '12 de Octubre', Madrid, Spain., Salman-Monte TC; Department of Rheumatology, Hospital del Mar/Parc de Salut Mar-IMIM, Barcelona, Spain., Narváez J; Deparment of Rheumatology, Hospital Universitario de Bellvitge-Instituto de Investigación Biomédica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, España., Vidal-Montal P; Deparment of Rheumatology, Hospital Universitario de Bellvitge-Instituto de Investigación Biomédica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, España., García-Villanueva MJ; Deparment of Rheumatology, Hospital Universitario Ramon y Cajal, Madrid, Spain., Garrote-Corral S; Deparment of Rheumatology, Hospital Universitario Ramon y Cajal, Madrid, Spain., Blazquez-Canamero MA; Deparment of Rheumatology, Severo Ochoa Hospital, Madrid, Spain., Fernandez-Cid CM; Department of Rheumatology, Hospital Universitario Virgen de Arrixaca, Murcia, Spain., Piqueras-García M; Department of Rheumatology, Hospital Universitario Virgen de Arrixaca, Murcia, Spain., Martínez-Barrio J; Deparment of Rheumatology, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Biomédica, Universidad Complutense de Madrid, Hospital Gregorio, Madrid, Spain., Sánchez-Lucas M; Deparment of Rheumatology, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Biomédica, Universidad Complutense de Madrid, Hospital Gregorio, Madrid, Spain., Cortés-Hernández J; Department of Rheumatology, Vall d'Hebron Research Institute, Barcelona, Spain., Penzo E; Department of Rheumatology, Vall d'Hebron Research Institute, Barcelona, Spain., Calvo J; Department of Rheumatology, Hospital Universitario de Araba, Vitoria, Spain., de Dios JR; Department of Rheumatology, Hospital Universitario de Araba, Vitoria, Spain., Alvarez-Rodríguez B; Department of Rheumatology, Hospital Universitario de Araba, Vitoria, Spain., Vasques-Rocha M; Department of Rheumatology, Hospital Universitario de Araba, Vitoria, Spain., Tomero E; Department of Rheumatology, Hospital Universitario de la Princesa, Madrid, Spain., Menor-Almagro R; Deparment of Rheumatology, Hospital Universitario de Jerez, Cádiz, Spain., Gandía M; Deparment of Rheumatology, Hospital Universitario de Jerez, Cádiz, Spain., Gómez-Puerta JA; Department of Rheumatology, Hospital Clinic and IDIBAPS, Barcelona, Spain., Frade-Sosa B; Department of Rheumatology, Hospital Clinic and IDIBAPS, Barcelona, Spain., Ramos-Giráldez C; Department of Rheumatology, Hospital Universitario Virgen de Valme, Sevilla, Spain. Rheumatology., Trapero-Pérez C; Department of Rheumatology, Hospital Universitario Virgen de Valme, Sevilla, Spain. Rheumatology., Diez E; Deparment of Rheumatology, Complejo Asistencial Universitario de León, León, Spain., Moriano C; Deparment of Rheumatology, Complejo Asistencial Universitario de León, León, Spain., Muñoz-Jiménez A; Department of Rheumatology, Hospital Universitario Virgen de Valme, Sevilla, Spain. Rheumatology., Pego-Reigosa JM; Department of Rheumatology, Complexo Hospitalario Universitario de Vigo, Vigo, Spain.; Galicia Sur Health Research Institute, Rheumatology and Inmuno-Mediated Diseases Reasearch Group (IRIDIS), Vigo, Spain.
Jazyk:	angličtina
Zdroj:	Rheumatology (Oxford, England) [Rheumatology (Oxford)] 2024 May 13. Date of Electronic Publication: 2024 May 13.
DOI:	10.1093/rheumatology/keae270
Abstrakt:	Objectives: The aims of this study were to investigate the prevalence of dose reduction in patients with SLE treated with belimumab (BEL) in Spain, analyze treatment modalities, and determine impact on control of disease activity. Methods: Retrospective longitudinal and multicentre study of SLE patients treated with BEL. Data on disease activity, treatments and outcomes were recorded before and after reduction (6-12 months), and they were compared. Results: A total of 324 patients were included. The dose was reduced in 29 patients (8.9%). The dosing interval was increased in 9 patients receiving subcutaneous BEL and in 6 patients receiving intravenous BEL. The dose per administration was reduced in 16 patients.Pre-reduction status was remission (2021 DORIS) in 15/26 patients (57.7%) and LLDAS in 23/26 patients (88.5%). After reduction, 2/24 patients (8.3%) and 3/22 patients (13.6%) lost remission at 6 months and 12 months, respectively (not statistically significant [NS]). As for LLDAS, 2/23 patients (8.7%) and 2/21 patients (9.5%) lost their status at 6 and 12 months, respectively (NS). Significantly fewer patients were taking glucocorticoids (GCs) at their 12-month visit, although the median dose of GCs was higher at the 12-month visit (5 [0.62-8.75] vs 2.5 [0-5] at baseline). Conclusion: Doses of BEL can be reduced with no relevant changes in disease activity-at least in the short term-in a significant percentage of patients, and most maintain the reduced dose. However, increased clinical or serologic activity may be observed in some patients. Consequently, tighter post-reduction follow-up is advisable. (© The Author(s) 2024. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu